As a shareholder, I am concerned about the damaging consequences of excessive executive compensation. New York Federal Reserve President William McDonough called upon companies to voluntarily address this problem by changing their compensation policies and practices. Bristol-Myers Squibb has demonstrated its willingness to be a leader on many issues of corporate responsibility; I would like our company also to take the lead in executive pay reforms.

Therefore as the beneficial owner, as defined under Rule 13(d)-3 of the General Rules and Regulations under the Securities Act of 1934, of 500 shares of Bristol-Myers Squibb common stock, I am submitting for inclusion in the next proxy statement, in accordance with Rule 14a-8 of these General Rules, the enclosed shareholder proposal. I am acting as a co-filer of this resolution, for which Ann Sink is acting as the primary filer. The proposal asks the Board of Directors to conduct an executive compensation review examining whether shareholder value would be enhanced if executive pay practices were significantly reformed.

As required by Rule 14a-8 I have held these shares for more than one year and will continue to hold the requisite number of shares through the date of the next stockholders' annual meeting. Proof of ownership will be provided upon request. One of the filing shareholders or our appointed representative will be present at the annual meeting to introduce the proposal.

Please send copies of all correspondence pertaining to this resolution to: Scott Klinger; United for a Fair Economy/Responsible Wealth; 37 Temple Place; Boston, MA 02111, who is assisting me in filing this resolution. United for a Fair Economy, the parent organization of the Responsible Wealth project, is a national non-profit organization working to address issues of income and wealth inequality both legislatively and through shareholder activism.

A commitment from Bristol-Myers Squibb to conduct the compensation review as requested would allow this resolution to be withdrawn. I believe that this proposal is in the best interest of Bristol-Myers Squibb and its shareholders.